The pleiotropic effects of statins

Harefuah

Volumn 144, Issue 8, 2005, Pages 577-582

  Wolfovitz, Efrat ^a  

^a BNAI ZION MEDICAL CENTER   (Israel)

Author keywords

Accelerated atheroscleros; Cholesterol; Isoprenoids; Mevalonate pathway; Pleiotropic effects; Statins

Indexed keywords

CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVALONIC ACID;

ATHEROSCLEROSIS; DISEASE COURSE; DRUG EFFECT; DRUG MECHANISM; PLEIOTROPY; REVIEW; ARTERIOSCLEROSIS; CLINICAL TRIAL; HUMAN; HYPERCHOLESTEROLEMIA; INFLAMMATION; OXIDATIVE STRESS;

ARTERIOSCLEROSIS; CLINICAL TRIALS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; INFLAMMATION; OXIDATIVE STRESS;

EID: 25444478911     PISSN: 00177768     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Takemoto M & Liao JK, Pleiotropic effects of 3-hydroxy-3- methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol, 2001; 21: 1712-1719.
2. Liao JK, Beyond lipid lowering: the role of statins in vascular protection. Int J Cardiol, 2002; 86: 5-18.
3. Wolfrum S, Jensen KS & Liao JK, Endothelium-dependent effects of statins. Arterioscler Thromb Vasc Biol, 2003; 23: 729-736.
4. Morikawa S, Takabe W, Mataki C & al, The effect of statins on mRNA levels of genes related to inflammation, coagulation, and vascular constriction in HUVEC. Human umbilical vein endothelial cells. J Atheroscler Thromb, 2002; 9: 178-83.
5. Gottsater A, Anwaar I, Lind P & al, Increasing plasma fibrinogen, unchanged levels of intraplatelet cyclic nucleotides, plasma endothelin-1, factor VII, and neopterin during cholesterol lowering with fluvastatin. Blood Coagul Fibrinolysis, 1999; 10: 133-40.
6. Nakamura T, Ushiyama C, Hirokawa K & al, Effect of cerivastatin on urinary albumin excretion plasma endothelin-1 concentration in type 2 diabetes patients with microalbuminuria and dyslipidemia. Am J Nephrol, 2001; 21: 449-54.
7. Dechend R, Gieffers J, Dietz R & al, Hydroxymethylglutaryl coenzyme a reductase inhibition reduces Chlamydia pneumoniae- induced cell interaction and activation. Circulation, 2003; 108: 261-265.
8. Weitz-Schmidt G, Statins as anti-inflammatory agents. Trends in pharmacol Sci, 2002; 23: 482-486.
9. Kwak BR, Mulhaupt F & Mach F, Atherosclerosis: anti-inflammatory and immunomodulatory activities of statins. Autoimmun Rev, 2003; 2: 332-338.
10. Hernandez C, Lecube A, Barbara G & al, Effects of hypolipidemic treatment on serum markers of vascular inflammation in dyslipidemic men. Med Sci Monit, 2003; 9: CR114-9.
11. Bickel C, Rupprecht HJ, Blankenberg S & al, Influence of HMG-CoA reductase inhibitors on markers of coagulation, systemic inflammation and soluble cell adhesion. Int J Cardiol, 2002; 82: 25-31.
12. Schilling M, Exner M, Mlekusch W & al, Statin therapy improves cardiovascular outcome of patients with peripheral artery disease. Eur Heart J, 2004; 25: 742-8.
13. Wiklund O, Mattsson-Hulten L, Hurt-Camejo E & Oscarsson J, Effects of simvastatin and atorvastatin on inflammation markers in plasma. Intern Med, 2002; 251: 338-347.
14. Chan KKW, Oza AM & Siu LL, The statins as anticancer agents. Clin Cancer Res, 2003; 9: 10-19.
15. Knapp AC, Huang J, Starling G & Kiener PA, Inhibitors of HMG-CoA reductase sensitize human smooth muscle cells to Fas-ligand and cytokine-induced cell death. Atherosclerosis, 2000; 152: 217-227.
16. Undas A, Brummel KE, Musial J & al, Simvastatin depresses blood clotting by inhibiting activation of pro thrombin, factor V, and factor XIII and by enhancing factor Va inactivation. Circulation, 2001; 103: 2248-2253.
17. Rosenson RS, Statins in atherosclerosis: lipid-lowering agents with antioxidant capabilities. Atherosclerosis, 2004; 173: 1-12.
18. Deakin S, Leview I, Guernier S & James RW, Simvastatin modulates expression of the PON1 gene and increases serum paraoxonase: a role for sterol regulatory element-binding protein-2. Arterioscler Thromb Vasc Biol, 2003; 23: 2083-2089.
19. Beltowski J, Wojcicka G & Jamroz A, Effect of 3-hydroxy-3- methylglutarylcoenzyme A reductase (statines) on tissue paraoxonase 1 and plasma platelet activating factor acetylhydrolase activities. J Cardiovasc Pharmacol, 2004; 43: 121-127.
20. Weis M, Heeschen C, Glassford AJ & Cooke JP, Statins have biphasic effects on Angiogenesis. Circulation, 2002; 105: 739-745.
21. Brouet A, Sonveaux P, Dessy C & al, Hsp90 and caveolin are key targets for the proangiogenic nitric oxide-mediated effects of statins. Circ Res, 2001; 89: 866-873.
22. Bauer DC, Mundy GR, Jamal SA & al, Use of statins and fracture. Arch Intern Med, 2004; 164: 146-152.
23. Maeda T, Mastsunuma A, Kawane T & Horiuchi N, Simvastatin promotes osteoblast differentiation and mineralization in MC3T3-E1 cells. Biochem Biophys Res Commun, 2001; 280: 874-877.
24. Nakagami H, Jensen KS & Liao JK, A novel pleiotropic effect of statins: prevention of cardiac hypertrophy by cholesterol-independent mechanisms. Ann Med, 2003; 35: 398-403.
25. Hasegawa H, Yamamoto R, Takano H & al, 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors prevent the development of cardiac hypertrophy and heart failure in rats. J Mol Cell Cardiol, 2003; 35: 953-960.
26. Nishikawa H, Miura S, Zhang B & al, Statins induce the regression of left ventricular mass in patients with angina. Circ J, 2004; 68: 121-125.
27. Ellis CJ & Scott R, Statins and coenzyme Q10. Lancet, 2003; 361: 1134-1135.
28. Casserly I & Topol E, Convergence of atherosclerosis and Alzheimer's disease: inflammation, cholesterol, and misfolded proteins. Lancet, 2004; 363: 1139-1146.
29. Stuve O, Youssef S, Steinman L & Zamvil SS, Statins as potential therapeutic agents in neuroinflammtory disorders. Curr Opin Neurol, 2003; 16: 393-401.
30. Neuhaus O, Stuve O, Zamvil SS & Hartung HP, Are Statins a treatment option for multiple sclerosis? Lancet Neurol, 2004; 3: 369-371.
31. Wong WLL, Dimitroulakos J, Minden MD & Penn LZ, HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia, 2002; 16: 508-519.
32. Buemi M, Senatore M, Corica F & al, Statins and progressive renal disease. Med Res Rev, 2002; 22: 76-84.
33. Usui H, Shikata K, Matsuda M & al, HMG-CoA reductase inhibitor ameliorates diabetic nephropathy by its pleiotropic effects in rats. Nephrol Dial Transplant, 2003; 18: 265-272.
34. Wenke K, Meiser B, Thiery J & al, Simvastatin initiated early after heart transplantation 8-year prospective experience. Circulation, 2003; 107: 93-97.
35. Johnson BA, Lacono AT, Zeevi A & al, Statin use is associated with improved function and survival of lung allografts. Am J Resp Crit Care Med, 2003; 167: 1271-1278.
36. Holdaas H & Jardine A, Acute renal allograft rejections, a role for statins?. Minerva Urol Nefrol, 2003; 55: 111-119.
37. McCarey DW, McInnes LB, Madhok R & al, Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controled trial. Lancet, 2004; 363: 2015-2021.
38. Noel B, Statins and lupus erythematosus. Rheumatology, 2004; 43: 397-398.
39. Klein R & Klein BEK, Do statins prevent age-related macular degeneration? Am J Ophthalmol, 2004; 137: 747-749.
40. Young-Xu Y, Chan A, Liao JK & al, Long-term statin use and psychological well-being. J Am Coll Cardiol, 2003; 42: 690-697.